ArticlePloS one2025
Burden of Chronic obstructive pulmonary disease in China: an analysis based on the GBD 2021 compared with the United States.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- COPD burden trends in China and G20 countries from GBD 2023 and Mendelian randomization.iScience · 2026Article
- Medication burden, adherence and health-related quality of life in COPD in China: a multilevel health system study.BMJ public health · 2026Article
- Divergent Trajectories and Risk Factor Attribution of Chronic Obstructive Pulmonary Disease Burden in China and the United States, 1990-2023: An Age-Period-Cohort Analysis with Projections to 2035 Based on the Global Burden of Disease Study 2023.International journal of chronic obstructive pulmonary disease · 2026Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease is an important disease affecting physical health worldwide, and the burden of this disease has been growing since 1991 for both China and the US.
objectiveTo examine the changes in the burden of COPD in both China and the US between 1990-2021.
methodsThe joinpoint analysis, age-Period-Cohort analysis, decomposition analysis, predictive analysis methods were used to describe prevalence, incidence, death, and disability-adjusted life years for COPD in China and the US.
resultsCompared with China, all four measures of the US COPD burden were higher than they had been in 1990. The burden of COPD increases with age in China. Conversely, in the US, the burden of COPD is getting younger. The epidemiological changes have contributed to an increasing burden of COPD in the US, but have led to a decline in the burden of COPD in China. By 2042, the number of cases in both countries will rise, especially the death rate in the US.
conclusionThe burden of COPD will not rapidly decline in the short term, both China and the US, as well as the global community, must take this disease seriously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.